PuraPharm Corp. Ltd. 1498

LONDON, October 02, 2026-- FORM 8.3

ZUG, Switzerland and BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company’s Phase 1 clinical data of its investigational CRISPR/Cas9 gene-edited allogeneic CAR T cell therapy, zugocabtagene geleucel (zugo-cel) targeting CD19 for autoimmune disease, will be presented at the American College of Rheumatology (ACR) Convergence 2026. Title: Safety and Efficacy of Anti-CD19 Allogeneic Chimeric Antigen Receptor

Global bond markets have recently steadied after a sharp sell off that pushed borrowing costs to their highest levels since 2002, and that pause is giving Australian biotech stocks fresh attention from investors hunting for focused growth themes rather than broad market bets. With balance sheets that look relatively reasonable and valuations that are not outright speculative, this basket of healthcare developers offers targeted exposure. This article examines three of the more notable biotech...